The US Food and Drug Administration (FDA) has approved Medtronic’s IN.PACT Admiral drug-coated balloon (DCB) for the treatment of long superficial femoral artery (SFA) lesions.

The indication allows the use of the DCB for up to 360mm SFA lesions in peripheral artery disease (PAD) patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The DCB works by dilating the vessel lumen, while the coated paclitaxel drug is set to reduce the formation of scar tissue to prevent artery narrowing.”

IN.PACT Admiral is designed as a primary endovascular therapy for treating claudication and restenosis in patients with SFA disease.

The DCB works by dilating the vessel lumen, while the coated paclitaxel drug is set to reduce the formation of scar tissue to prevent artery narrowing.

Medtronic Peripheral business vice-president and general manager Mark Pacyna said: “With this approval, IN.PACT Admiral is now indicated to treat the longest lesions of any commercially-available DCB or peripheral stent in the US, providing physicians with additional confidence in using this DCB as part of their treatment algorithm.

“In partnership with the clinical community, we look forward to continued collaboration as we work to address additional treatment challenges in PAD with this device.”

The FDA approval follows the review of findings from a total of 227 subjects across the complex lesion imaging cohorts in the IN.PACT Global Study.

Study evaluation included long lesion, in-stent restenosis and chronic total occlusion (CTO) groups whose lesions were greater than 180mm.

Results demonstrated 89.1% one-year patency rate at day 360 and 7.1% clinically-driven target revascularisation (CD-TLR) rate.

The IN.PACT Admiral DCB secured the European CE-Mark in 2009 for PAD treatment and the US FDA approval in 2014 for superficial femoral and popliteal arteries.